Status:

COMPLETED

Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples

Lead Sponsor:

University of Western Ontario, Canada

Conditions:

Neuroendocrine Carcinoma (Carcinoid)

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

The goal of this study is to compare several methods for measurement of Chromogranin A in their ability to serve as a marker for disease activity in patients with neuroendocrine tumors. Further, in a...

Detailed Description

Patient group: patients with neuroendocrine tumors (active or inactive) Healthy volunteers

Eligibility Criteria

Inclusion

  • Patients:
  • having neuro-endocrine disease

Exclusion

  • age below 18 or above 70 years
  • prostate cancer
  • kidney failure (estimated GF \< 30 mL/Min)
  • heart failure
  • chronic atrophic gastritis
  • pregnancy
  • Healthy subjects:
  • Inclusion Criteria:
  • healthy

Key Trial Info

Start Date :

June 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2012

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT01216267

Start Date

June 1 2010

End Date

January 1 2012

Last Update

January 16 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

London Health Sciences Center and St. Joseph's Health Care

London, Ontario, Canada, N6A 4V2